Basilea Pharmaceutica (XSWX:BSLN) Total Inventories: CHF21.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF52.00
GF Value CHF57.71
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Total Inventories?

Basilea Pharmaceutica XSWX:BSLN -2.07% 61 Total Inventories is CHF21.6 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.71 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Basilea Pharmaceutica's total inventories for the quarter that ended in Dec. 2025 was CHF21.6 Mil. Basilea Pharmaceutica's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was CHF22.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Basilea Pharmaceutica's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was CHF2.17.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Basilea Pharmaceutica's Days Inventory for the six months ended in Dec. 2025 was 267.12.

Inventory Turnover measures how fast the company turns over its inventory within a year. Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.68.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Basilea Pharmaceutica's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.17.

Basilea Pharmaceutica  (XSWX:BSLN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Basilea Pharmaceutica's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(159.8+0.75 * 13.491+0.5 * 21.558-154.058
-0-0)/12.292
=2.17

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Basilea Pharmaceutica's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=22.0915/15.093*365 / 2
=267.12

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Basilea Pharmaceutica's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=15.093 / 22.0915
=0.68

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Basilea Pharmaceutica's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=22.0915 / 128.42
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Basilea Pharmaceutica Total Inventories Related Terms

Basilea Pharmaceutica Total Inventories Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Total Inventories Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.78 24.24 26.41 31.61 21.56

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.41 31.38 31.61 22.63 21.56
XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of CHF21.6 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Total Inventories of CHF21.6 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Total Inventories too high?
Basilea Pharmaceutica's current Total Inventories is CHF21.6 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Total Inventories compare to VRTX and REGN?
Basilea Pharmaceutica's Total Inventories of CHF21.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Total Inventories is CHF21.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.71, compared to a current price of CHF52.00 — trading 9.9% below its estimated fair value. The current Total Inventories is CHF21.6 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Total Inventories is CHF21.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF52.00 is trading 9.9% below its estimated GF Value™ of CHF57.71. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for XSWX:BSLN:

  • Total Inventories: CHF21.6 Mil
  • GF Value™: CHF57.71 vs. price of CHF52.00 (9.9% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF52.00
Price
CHF57.71
GF Value